Akums q4 revenue rises to rs 11.58 billion, net profit soars 135%

Akums Drugs & Pharmaceuticals Ltd. reported a strong improvement in profitability for the fourth quarter and full year ended March 31, 2026. This was mainly driven by robust growth in its core CDMO (Contract Development and Manufacturing Organization) business, improved operational efficiency, and continued international expansion. In the fourth quarter of fiscal year 2026 (Q4 FY26), the company recorded operating revenue of INR 11.58 billion, up 9.7% year-on-year from INR 10.56 billion in the same period last year. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) surged 61.6% year-on-year to INR 1.52 billion, while the EBITDA margin rose significantly from 8.9% to 13.1%.

Adjusted PAT for the fourth quarter surged 135% year-on-year, more than doubling from INR 350 million in Q4 FY2025 to INR 830 million. The PAT margin also improved from 3.3% in the same period last year to 7.0%.

From a full fiscal year perspective, AkzoNobel reported an operating income of 43.59 billion rupees for the fiscal year 2026, an increase of 5.9% year-on-year; adjusted EBITDA grew by 13.3% to 5.22 billion rupees. The adjusted net profit for the year increased by 27.3% to 2.76 billion rupees.

In this quarter, the company's CDMO business remained the main growth engine. CDMO business revenue grew from 8.4 billion rupees in the fourth quarter of fiscal year 2025 to 9.52 billion rupees, while the EBITDA of this segment increased significantly by 54.9% year-on-year to 1.37 billion rupees. Supported by stronger customer engagement, higher capacity utilization, and focused execution, the EBITDA margin of this segment expanded from 10.6% to 14.4%.

In evaluating the performance, Sanjeev Jain said: “Fiscal 2026 has been a steady year forward for Akums. We continued to build long-term capabilities while achieving healthy growth in revenue and profitability. The milestones we achieved in regulatory compliance, our progress in international markets, and our strong domestic performance all reflect our commitment to building Akums into a global pharmaceutical company and a trusted partner for our customers.”

Image source: Internet

Sandeep Jain added, "The performance in the fourth quarter and the full year of fiscal 2026 shows a comprehensive improvement in core operational metrics. Our CDMO business continues to perform well, and we will remain focused on enhancing capacity utilization, strictly controlling costs, and looking towards future growth. We are currently advancing several digitalization and automation initiatives that will create long-term value for the entire organization."

Akkumis made significant progress in expanding its global footprint during the fiscal year 2026. The company completed its first commercial supply of formulations to the European market, with its oral solid and liquid formulation facilities obtaining EU GMP (Good Manufacturing Practice) certification. It also received its first approval from the UK's MHRA (Medicines and Healthcare products Regulatory Agency) for Rivaroxaban. Its injectable facility received approval from Brazil's ANVISA (National Health Surveillance Agency), and the groundbreaking ceremony for a pharmaceutical factory in Zambia marked another milestone in its international expansion strategy.

The domestic branded formulation business remained stable during the quarter, recording revenue of 1.02 billion rupees, while the segment's annual revenue grew by 2.9% to 4.46 billion rupees. During the fiscal year 2026, the segment's EBITDA increased by 17% year-on-year to 900 million rupees.

The international branded formulations business recorded quarterly revenue of 360 million rupees, with annual revenue stable at 1.43 billion rupees. However, the EBITDA for this segment grew by 32.3% year-on-year to 360 million rupees, indicating an improvement in operational efficiency.

Akhums’s Trade Generics business also showed signs of recovery, turning EBITDA positive in the fourth quarter of FY2026, with EBITDA reaching INR 14 million. For the full year, the segment’s EBITDA loss narrowed significantly from INR 280 million in FY2025 to INR 100 million.

Although the overall performance remained positive, the API business continued to face pressure due to pricing challenges. API revenue declined from INR 500 million in the same quarter last year to INR 410 million in Q4 FY2026, and the segment recorded an operating loss of INR 120 million. However, the company said it remains focused on product-mix optimization, cost control, and improving operational efficiency to support long-term sustainable growth.